- Home
- ZIP vs SION Comparison
ZIP vs SION Comparison
Compare ZIP & SION Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZIP
- SION
- Stock Information
- Founded
- ZIP 2010
- SION 2019
- Country
- ZIP United States
- SION United States
- Employees
- ZIP N/A
- SION N/A
- Industry
- ZIP Diversified Commercial Services
- SION
- Sector
- ZIP Consumer Discretionary
- SION
- Exchange
- ZIP Nasdaq
- SION NYSE
- Market Cap
- ZIP 508.3M
- SION 564.4M
- IPO Year
- ZIP 2021
- SION 2025
- Fundamental
- Price
- ZIP $5.02
- SION $14.49
- Analyst Decision
- ZIP Hold
- SION Strong Buy
- Analyst Count
- ZIP 5
- SION 1
- Target Price
- ZIP $7.40
- SION $32.00
- AVG Volume (30 Days)
- ZIP 1.1M
- SION 127.9K
- Earning Date
- ZIP 08-06-2025
- SION 05-12-2025
- Dividend Yield
- ZIP N/A
- SION N/A
- EPS Growth
- ZIP N/A
- SION N/A
- EPS
- ZIP N/A
- SION N/A
- Revenue
- ZIP $461,827,000.00
- SION N/A
- Revenue This Year
- ZIP N/A
- SION N/A
- Revenue Next Year
- ZIP $11.97
- SION N/A
- P/E Ratio
- ZIP N/A
- SION N/A
- Revenue Growth
- ZIP N/A
- SION N/A
- 52 Week Low
- ZIP $4.25
- SION $7.26
- 52 Week High
- ZIP $11.25
- SION $25.19
- Technical
- Relative Strength Index (RSI)
- ZIP 38.82
- SION N/A
- Support Level
- ZIP $4.92
- SION N/A
- Resistance Level
- ZIP $6.48
- SION N/A
- Average True Range (ATR)
- ZIP 0.35
- SION 0.00
- MACD
- ZIP -0.14
- SION 0.00
- Stochastic Oscillator
- ZIP 5.83
- SION 0.00
About ZIP ZipRecruiter Inc.
ZipRecruiter Inc is an online employment marketplace. It connects millions of job seekers with companies of all sizes. It is a two-sided marketplace for work that simplifies the job market for both job seekers and employers. Unlike traditional online job sites, ZipRecruiter works like a matchmaker curating job opportunities for job seekers, and candidates for employers.
About SION SIONNA THERAPEUTICS INC
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.